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Abstract
Background Tamoxifen is widely used as endocrine therapy for
oestrogen-receptor-positive breast cancer. However, many of
these patients experience recurrence despite tamoxifen therapy
by incompletely understood mechanisms. In the present report
we propose that tamoxifen resistance may be due to differences
in activity of metabolic enzymes as a result of genetic
polymorphism. Cytochrome P450 2D6 (CYP2D6) and
sulfotransferase 1A1 (SULT1A1) are polymorphic and are
involved in the metabolism of tamoxifen. The CYP2D6*4 and
SULT1A1*2 genotypes result in decreased enzyme activity. We
therefore investigated the genotypes of CYP2D6 and SULT1A1
in 226 breast cancer patients participating in a trial of adjuvant
tamoxifen treatment in order to validate the benefit from the
therapy.
Methods The patients were genotyped using PCR followed by
cleavage with restriction enzymes.
Results Carriers of the CYP2D6*4  allele demonstrated a
decreased risk of recurrence when treated with tamoxifen
(relative risk = 0.28, 95% confidence interval = 0.11–0.74, P =
0.0089). A similar pattern was seen among the SULT1A1*1
homozygotes (relative risk = 0.48, 95% confidence interval =
0.21–1.12, P = 0.074). The combination of CYP2D6*4 and/or
SULT1A1*1/*1 genotypes comprised 60% of the patients and
showed a 62% decreased risk of distant recurrence with
tamoxifen (relative risk = 0.38, 95% confidence interval = 0.19–
0.74, P = 0.0041).
Conclusion The present study suggests that genotype of
metabolic enzymes might be useful as a guide for adjuvant
endocrine treatment of postmenopausal breast cancer patients.
However, results are in contradiction to prior hypotheses and
the present sample size is relatively small. Findings therefore
need to be confirmed in a larger cohort.
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Introduction
The majority of breast tumours express oestrogen recep-
tors (ERs). Several studies have shown that 5 years of
tamoxifen therapy in breast cancer patients with receptor-
positive tumours reduces the risk of recurrence and mortal-
ity [1]. However, about 30% of patients acquire tamoxifen
resistance and relapse in the disease [1]. Several possible
mechanisms for this have been suggested [2-4].
Tamoxifen and its metabolites compete with endogenous
oestrogen for the ligand-binding domain of the ER. The
complex formation between tamoxifen, or its active metab-
olites, and the ER inhibits recruitment of co-activator com-
plexes necessary for transcription of oestrogen-responsive
genes [5]. The biotransformation of tamoxifen is mediated
by cytochrome P450 enzymes mainly through demethyla-
tion and hydroxylation to form several primary metabolites,
principally 4-OH-tamoxifen, α-OH-tamoxifen, N-desmethyl-
tamoxifen, and 4-OH-N-desmethyl-tamoxifen. 4-OH-
tamoxifen is considered to be a more potent anti-oestrogen
than the mother substance and is capable of binding the
ER with greater affinity [6,7]. From experimental studies it
BSA = bovine serum albumin; CI = confidence interval; CYP2D6 = cytochrome P450 2D6; ER = oestrogen receptor; PCR = polymerase chain reac-
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has been shown that the transformation of tamoxifen into 4-
OH-tamoxifen is mainly catalysed by the liver enzyme
CYP2D6 [8,9]. A further step in the metabolism of
tamoxifen is sulfate conjugation, catalysed by members of
the sulfotransferase family, which generally increase the
solubility and facilitate excretion of the drug. Sulfotrans-
ferase 1A1 (SULT1A1) is a major form of phenol sulfotrans-
ferase in the adult human liver, and it has been shown to be
the primary sulfotransferase responsible for the sulfation of
4-OH-tamoxifen [10,11].
Polymorphisms affecting the enzyme activity have been
found in both cytochrome P450 2D6 (CYP2D6) and
SULT1A1 [12,13]. Among Caucasians the most frequent
inactivating polymorphism in CYP2D6 is the CYP2D6*4
allele, which generates a G → A transition at nucleotide
1934 leading to a disruption of the reading frame and to a
truncated non-functional gene product [14]. The most
common polymorphism in the SULT1A1 gene is a G → A
transition at nucleotide 638, resulting in an arginine to his-
tidine substitution at the conserved amino acid 213. This
allele, SULT1A1*2, is correlated with diminished capacity
to sulfate SULT1A1 substrates [15]. The aim of the present
study was to investigate the genotypes of CYP2D6 and
SULT1A1  in breast cancer patients with and without
tamoxifen treatment in order to validate the relation
between the genotype and the benefit from tamoxifen
therapy.
Materials and methods
Patients
The Stockholm Breast Cancer Group started a trial in 1976
to compare postoperative radiotherapy with adjuvant
chemotherapy [16]. Both premenopausal patients and
postmenopausal patients (age ≤ 70 years) with a unilateral,
operable breast cancer were included. The patients were
required to have either histological verified lymph node
metastases or a tumour diameter exceeding 30 mm. All
patients were treated with a modified radical mastectomy.
Using a 2 × 2 factorial study design, the postmenopausal
patients were then randomised to a comparison of adjuvant
tamoxifen treatment or no endocrine treatment in a total of
four treatment groups: adjuvant chemotherapy, adjuvant
chemotherapy plus tamoxifen, radiotherapy, and radiother-
apy plus tamoxifen. Tamoxifen was given postoperatively at
a dose of 40 mg daily for 2 years and was initiated within
4–6 weeks of surgery. The mean follow-up time was 10.7
years (range, 0.24–18.6 years). Of the 679 postmenopau-
sal breast cancer patients included in the trial, fresh frozen
tumour tissues of 226 patients were available for the cur-
rent investigation, of whom 112 had received tamoxifen
therapy. The number of distant recurrences was 64 in the
tamoxifen-treated group and 84 in the group not receiving
tamoxifen. Furthermore, the fractions of lymph-node-posi-
tive and ER-positive tumours were 88/89 and 71/70,
respectively, and the percentage of large tumours (>20
mm) was 57/61 in the initial study and the current study.
Polymerase chain reaction
DNA was isolated from fresh-frozen tumour tissues using
phenol, phenol/chloroform (1:1), and chloroform, was pre-
cipitated with ethanol and was re-dissolved in sterile water.
The CYP2D6 and SULT1A1 genes were amplified with
PCR in separate reactions using 30 ng DNA and 60 ng
DNA, respectively. The primer sequences used in the PCR
of CYP2D6 and SULT1A1 were adopted from Hanioka
and colleagues [14] and Coughtrie and colleagues [17].
The following PCR reagents were added to a reaction vol-
ume of 20 µl: 2 mM MgCl2, 0.2 mM dNTPs, 0.5 units Taq
DNA polymerase, and 1 µM each of forward and reverse
primer in 1 × PCR buffer. The amplifications were carried
out in a PTC-200 Peltier Thermal Cycler DNA Engine (MJ
Research™ Inc, Waltham, MA, USA). An initial denaturation
at 94°C for 3 min was followed by 40–43 cycles of 30 s at
94°C, 30 s of annealing at 63°C, and 40 s for extension at
72°C. An extension period of 5 min followed the final cycle.
Restriction fragment length polymorphism
The  CYP2D6  and  SULT1A1  polymorphisms were
detected using restriction enzymes. The MvaI enzyme dis-
tinguishes between the CYP2D6*4  allele and other
CYP2D6 alleles. The polymorphic allele CYP2D6*4 lacks
the restriction site, and is thereby retained as one fragment.
Alleles harbouring the MvaI restriction site generate two
fragments and are classified as CYP2D6*1. SULT1A1*1
(wild-type allele) has a restriction site recognised by the
HaeII enzyme, while the polymorphic SULT1A1*2  lacks
this site.
Ten units of MvaI (Fermentas, Stockholm, Sweden) and 1.5
µl R+ Buffer (Fermentas) were added to each tube of
CYP2D6 PCR products and were incubated at 37°C for
2.5 hours. The SULT1A1 PCR products were incubated
with 5 units of the restriction enzyme HaeII (New England
BioLabs, Beverly, MA, USA) in a 20 µl reaction mixture con-
taining 1 × NE (50 mM potassium acetate, 20 mM Tris-ace-
tate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH
7.9) buffer (New England Bioloabs), supplemented with
100 µg/ml BSA. After digestion, fragments were resolved
by electrophoresis on a 3% (w/v) agarose gel containing 1
× TBE (89 mM Tris, 89 mM Boric acid, 2 mM EDTA, pH
8.4) buffer and ethidium bromide (0.5 µg/µl). A 100-mole-
cule weigh ladder was used as the base pair marker. The
gel was finally processed in a UV detector (Spectromics
Corporation, New York, USA). To confirm the reliability of
the restriction fragment length polymorphism method, a
number of randomly selected samples were DNA
sequenced. No differences in genotype were obtained
between the methods.Available online http://breast-cancer-research.com/content/7/3/R284
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Statistical analyses
Statistical analyses were performed with the Statistica 6.0
software program (Statsoft Inc., Tulsa, OK, USA). We com-
pared distant recurrence-free survival by genotype and by
endocrine treatment with the log-rank test. The relative risk
(RR) of distant recurrences among ER-positive patients
treated with and without tamoxifen was assessed using
Cox proportional hazard regression, and adjustments for
age, tumour size, and lymph node status were performed.
Results
Information on tumour size, nodal involvement, ER status
and tamoxifen therapy of 226 patients is presented in Table
1. The patients were genotyped according to the
CYP2D6*4 and the SULT1A1*1 or SULT1A1*2 alleles.
There were no significant differences in tumour character-
istics between genotypes (Table 1).
The distributions of allele frequencies were 0.163 and
0.386 for CYP2D6*4 and SULT1A1*2, respectively. Since
the CYP2D6*4 homozygotes were few, patients with at
least one CYP2D6*4 allele were combined in the statistical
analyses. Similarly, patients carrying the SULT1A1*2 allele
were grouped together. To investigate whether the geno-
type had a prognostic value, in terms of distant recurrence-
free survival, ER-positive and ER-negative patients
homozygous for CYP2D6*1 alleles were compared with
carriers of the CYP2D6*4  allele, and the patients
homozygous for the SULT1A1*1  allele were compared
with carriers of the SULT1A1*2 allele. No statistical differ-
ences in distant recurrences were found according to gen-
otype (data not shown). To assess the benefit from
tamoxifen treatment, distant recurrence-free survival was
only calculated in ER-positive patients.
Distant recurrence-free survival for CYP2D6*1  homozy-
gotes, for CYP2D6*4 heterozygotes and homozygotes, for
SULT1A1*1 homozygotes, and for SULT1A1*2 heterozy-
gotes and homozygotes are shown in Figs 1a,b and 2a,b,
respectively, and are presented in Table 2. Patients pos-
sessing at least one CYP2D6*4 allele had better survival
when randomised to tamoxifen compared with those who
were not randomised to tamoxifen (P = 0.0089), as also
demonstrated by the significantly decreased relative risk
(RR = 0.28, 95% confidence interval [CI] = 0.11–0.74).
Among patients homozygous for the CYP2D6*1 genotype,
the outcome was approximately equal between tamoxifen-
treated and non-tamoxifen-treated patients (P = 0.75). A
tendency towards improved distant recurrence-free sur-
vival in SULT1A1*1  homozygous patients treated with
tamoxifen, compared with those receiving no tamoxifen,
was found (P = 0.074, RR = 0.48, 95% CI = 0.21–1.12)
(Fig. 2a). Finally, no influence of tamoxifen therapy on dis-
tant recurrence-free survival was found in carriers of the
SULT1A1*2 allele (P = 0.48) (Fig. 2b).
The genotypes linked to the benefit from tamoxifen treat-
ment are combined in Fig. 3 as well as in Table 2. In
patients harbouring the combination with at least one
CYP2D6*4  allele and/or a homozygous SULT1A1*1,
tamoxifen treatment significantly improved survival (P  =
0.0041, RR = 0.38, 95% CI = 0.19–0.74). We also com-
pared non-beneficial alleles (i.e. CYP2D6*1 homozygotes
and SULT1A1*2 carriers), and no statistical difference was
Table 1
Genotype, tumour characteristics and endocrine therapy of the total study population (n = 226), including both oestrogen receptor 
(ER)-positive and ER-negative patients
Characteristic Genotype [n (%)]
CYP2D6*1/*1 CYP2D6*1/*4 CYP2D6*4/*4 SULT1A1*1/*1 SULT1A1*1/*2 SULT1A1*2/*2
Nodal involvementa, tumour size
Node-, >30 mm 19 (76.0) 5 (20.0) 1 (4.0) 6 (24.0) 11 (44.0) 8 (32.0)
Node+, ≤ 20 mm 66 (74.2) 18 (20.2) 5 (5.6) 30 (33.7) 49 (55.1) 10 (11.2)
Node+, >20 mm 77 (68.8) 32 (28.6) 3 (2.7) 43 (38.4) 59 (52.7) 10 (8.9)
Receptor statusb
ER-negative 50 (74.6) 12 (17.9) 5 (7.5) 23 (34.3) 35 (52.2) 9 (13.4)
ER-positive 109 (69.9) 43 (27.6) 4 (2.6) 56 (35.9) 82 (52.6) 18 (11.5)
Endocrine therapy
Tamoxifen 77 (68.8) 28 (25.0) 7 (6.3) 37 (33.0) 60 (53.6) 15 (13.4)
No tamoxifen 85 (74.6) 27 (23.7) 2 (1.8) 42 (36.8) 59 (51.8) 13 (11.4)
aNodal involvement: node+, node-positive; node-, node-negative.
bER data from three patients were missing.Breast Cancer Research    Vol 7 No 3    Wegman et al.
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found in distant recurrence-free survival (P = 0.57, RR =
1.22, 95% CI = 0.61–2.4). A comparison of the RRs of dis-
tant recurrence, calculated for each combined genotype
and adjusted for age, tumour size and lymph node status,
demonstrated that the risk reduction with tamoxifen was
significantly higher in patients harbouring the combination
of CYP2D6*4  and/or SULT1A1*1/*1  (P  = 0.018) (Fig.
3a,b and Table 2).
Discussion
We observed a significantly improved benefit from
tamoxifen in patients carrying the CYP2D6*4 allele and/or
patients homozygous for SULT1A1*1 (P = 0.018), com-
pared with patients homozygous for the CYP2D6*1 and
carriers of the SULT1A1*2 allele (Fig. 3). To our knowledge
this is the first report of the influence of the CYP2D6 gen-
otype on tamoxifen therapy, while the influence of the
SULT1A1*1 allele has been investigated by Nowell and
colleagues [13]. In agreement with the tendency found in
the present report, Nowell and colleagues showed that the
high-activity allele SULT1A1*1 contributed significantly to
Figure 1
Distant recurrence-free survival among postmenopausal women with  oestrogen-receptor-positive breast cancers, in relation to the CYP2D6  genotype and adjuvant tamoxifen treatment Distant recurrence-free survival among postmenopausal women with 
oestrogen-receptor-positive breast cancers, in relation to the CYP2D6 
genotype and adjuvant tamoxifen treatment. Solid line, patients receiv-
ing tamoxifen (Tam+); dashed line, patients who did not receive 
tamoxifen (Tam-). (a) Patients homozygous for the CYP2D6*1 allele. 
The number of events for Tam+ and Tam- were 25 and 27, respectively. 
(b). Patients homozygous or heterozygous for the CYP2D6*4 allele 
(null allele). The number of events for Tam+ and Tam- were 6 and 15, 
respectively.
Figure 2
Distant recurrence-free survival of postmenopausal, oestrogen-recep- tor-positive breast cancer patients in relation to the SULT1A1 genotype  and adjuvant tamoxifen therapy Distant recurrence-free survival of postmenopausal, oestrogen-recep-
tor-positive breast cancer patients in relation to the SULT1A1 genotype 
and adjuvant tamoxifen therapy. Solid line, patients receiving tamoxifen 
(Tam+); dashed line, patients who did not receive tamoxifen (Tam-). (a) 
Patients homozygous for the SULT1A1*1 allele. The number of events 
for Tam+ and Tam- were 9 and 16, respectively. (b) Patients 
homozygous or heterozygous for the SULT1A1*2 allele (low-activity 
allele). The number of events for Tam+ and Tam- were 24 and 26, 
respectively.Available online http://breast-cancer-research.com/content/7/3/R284
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tamoxifen response [13]. Those authors suggested that
sulfation may affect bioavailability of 4-OH-tamoxifen by
reduced clearance of the sulfated metabolite. This may pro-
vide a genotype-dependent reservoir of inactivated metab-
olite, which can be desulfated by steroid sulfatase
expressed in breast tumours and can be recovered to the
active 4-OH-tamoxifen, leading to a prolonged anti-oestro-
gen effect [18].
Coller and colleagues [19] and other workers [8,9] have
demonstrated in experimental studies that the CYP2D6
genotype is a determinant of the ability to form 4-OH-
tamoxifen. However, a clinical study by Stearns and col-
leagues [20] revealed that inhibition of CYP2D6 had no
significant effect on 4-OH-tamoxifen concentration. We
propose in the present study that genotypes of CYP2D6,
which produce a large amount of the ER-active 4-OH-
tamoxifen, would be beneficial for the tamoxifen-treated
patients. As shown in the present study, patients with at
least one CYP2D6*4 allele demonstrated better response
to tamoxifen treatment than patients homozygous for the
CYP2D6*1 allele. This is in contrast to the main hypothe-
ses where the CYP2D6*1 homozygous patients are sup-
posed to generate the active metabolite 4-OH-tamoxifen
more readily and thereby have improved response of
tamoxifen. Our results were obtained from a small number
of patients, and therefore the association of the genotype
and the benefit of tamoxifen treatment may be a coinci-
dence. An absent or decreased CYP2D6-dependent 4-
hydroxylation is, however, compensated by CYP2C9 and
CYP3A4 to the overall formation of 4-OH-tamoxifen, but
the reaction proceeds at a lower rate [19,21].
Interestingly, an additional active tamoxifen metabolite, 4-
OH-N-desmethyl-tamoxifen (endoxifen), has been recently
discovered by Stearns and colleagues [20]. Endoxifen may
have clinical relevance since the metabolite inhibits MCF7
cell proliferation with equal potency as does 4-OH-
tamoxifen, and it is present in higher plasma concentration
in humans than 4-OH-tamoxifen. Endoxifen is mainly syn-
thesised by CYP3A4-mediated N-demethylation of
tamoxifen and a subsequent 4-hydroxylation by CYP2D6.
In humans there are a large number of different polymorphic
sites in the CYP2D6 gene, and the vast majority is present
in a very low frequency.
In the present study we screened for the most common
inactivating polymorphism in CYP2D6, the CYP2D6*4
allele, which is present at a frequency of approximately 21–
29%. Other less common inactive alleles are CYP2D6*3
and CYP2D6*5, representing around 1% and 4%, respec-
tively, of all CYP2D6  alleles [22]. Among alleles with
decreased enzyme activity the CYP2D6*41 allele identifies
a large proportion of the intermediate metabolisers [23].
The restriction fragment length polymorphism technique
that we used identifies a restriction site not found in the
CYP2D6*4 allele but that is present in other CYP2D6 alle-
les. This results in misclassification of the carriers of
CYP2D6*3 and CYP2D6*5 alleles, which could occur in a
few cases but would have a minor influence on the results.
Table 2
Statistics of oestrogen-receptor-positive patients: association between tamoxifen therapy/no tamoxifen therapy (Tam+/Tam-) and 
distant recurrence rate, stratified according to genotype
Genotype Tamoxifen therapy Number of patientsa Number of recurrences Recurrence rate ratio 
(95% confidence interval)
P value
SULT1A1*1/*1† Tam- 29 16 1.0
Tam+ 26 9 0.48 (0.21 – 1.12) 0.074
SULT1A1*2† Tam- 49 26 1.0
Tam+ 50 24 0.82 (0.47 – 1.43) 0.48
CYP2D6*1/*1‡ Tam- 55 27 1.0
Tam+ 52 25 0.91 (0.53– 1.57) 0.75
CYP2D6*4‡ Tam- 23 15 1.0
Tam+ 24 6 0.28 (0.11 – 0.74) 0.0089
SULT1A1*1/*1 and/or CYP2D6*4§ Tam- 45 27 1.0
Tam+ 43 15 0.38 (0.19– 0.74) 0.0041
SULT1A1*2 and CYP2D6*1/*1§ Tam- 33 18 1.0
Tam+ 33 15 1.22 (0.61– 2.40) 0.57
The relative risks of distant recurrence, calculated for each combined genotype are adjusted for age, tumour size and lymph node status.
aFollow-up data of two patients were missing.
†,‡,§The risk ratio was first calculated separately for each genotype and genotype combination. Second, the test for interaction between the risk 
ratios was performed by Cox regression: †P = 0.27, ‡P = 0.064, and §P = 0.018. The risk ratio for patients not receiving tamoxifen (Tam-) is 
calculated as 1.0.Breast Cancer Research    Vol 7 No 3    Wegman et al.
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The definition of CYP2D6*1  used in the present study
mainly constitutes the normal activity alleles CYP2D6*1
and CYP2D6*2, which represent a rather high frequency in
a Caucasian population [22]. In the regression analysis we
combined CYP2D6*4 heterozygotes and homozygotes in
one group since the number of homozygous CYP2D6*4
patients was low. Some studies have shown that the
hydroxylation ratios are significantly different between the
homozygous and heterozygous genotypes, demonstrating
intermediate hydroxylation ratios in heterozygous geno-
types. There is also support, however, for the hypothesis
that only CYP2D6*4 homozygotes will demonstrate altered
pharmacokinetics for a given drug [24].
Conclusion
The variability in distant recurrence-free survival found in
endocrine-treated patients may be a result of differences in
drug metabolism. The genotype of metabolic enzymes
might thus be useful as a guide for adjuvant endocrine
treatment of postmenopausal breast cancer patients. How-
ever, our results contradict the main hypotheses and the
present sample size is relatively small. Our findings there-
fore need confirmation in a larger cohort.
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